Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Kuilman

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Oncoimmunology|December 5, 2022
<i>SERPINB9</i> is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade responseSofía Ibáñez-Molero, Alex van Vliet, Joanna Pozniak, et al.
Oncotarget|April 30, 2016
Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferationTesa M Severson, Ekaterina Nevedomskaya, Justine Peeters, et al.
EMBO Molecular Medicine|June 25, 2015
Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenograftsKristel Kemper, Oscar Krijgsman, Paulien Cornelissen-Steijger, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 14, 2015
Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastasesFleur Weeber, Marc van de Wetering, Marlous Hoogstraat, et al.
BMC Bioinformatics|October 6, 2018
XenofilteR: computational deconvolution of mouse and human reads in tumor xenograft sequence dataRoelof J C Kluin, Kristel Kemper, Thomas Kuilman, et al.
Cell Reports. Medicine|June 10, 2022
RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cellsZhengkui Zhang, Xiangjun Kong, Maarten A Ligtenberg, et al.
Pigment Cell & Melanoma Research|December 18, 2014
Detailed imaging and genetic analysis reveal a secondary BRAF(L505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenibMarlous Hoogstraat, Christa G Gadellaa-van Hooijdonk, Inge Ubink, et al.
Plos One|May 25, 2019
Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancerWillemijn S M E Theelen, Thomas Kuilman, Katja Schulze, et al.
Cell Reports|July 5, 2016
Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in PatientsEkaterina A Semenova, Min-Chul Kwon, Kim Monkhorst, et al.
Cell Reports|June 21, 2016
BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived XenograftsKristel Kemper, Oscar Krijgsman, Xiangjun Kong, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Oncoimmunology|December 5, 2022
<i>SERPINB9</i> is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade responseSofía Ibáñez-Molero, Alex van Vliet, Joanna Pozniak, et al.
Oncotarget|April 30, 2016
Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferationTesa M Severson, Ekaterina Nevedomskaya, Justine Peeters, et al.
EMBO Molecular Medicine|June 25, 2015
Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenograftsKristel Kemper, Oscar Krijgsman, Paulien Cornelissen-Steijger, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 14, 2015
Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastasesFleur Weeber, Marc van de Wetering, Marlous Hoogstraat, et al.
BMC Bioinformatics|October 6, 2018
XenofilteR: computational deconvolution of mouse and human reads in tumor xenograft sequence dataRoelof J C Kluin, Kristel Kemper, Thomas Kuilman, et al.
Cell Reports. Medicine|June 10, 2022
RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cellsZhengkui Zhang, Xiangjun Kong, Maarten A Ligtenberg, et al.
Pigment Cell & Melanoma Research|December 18, 2014
Detailed imaging and genetic analysis reveal a secondary BRAF(L505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenibMarlous Hoogstraat, Christa G Gadellaa-van Hooijdonk, Inge Ubink, et al.
Plos One|May 25, 2019
Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancerWillemijn S M E Theelen, Thomas Kuilman, Katja Schulze, et al.
Cell Reports|July 5, 2016
Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in PatientsEkaterina A Semenova, Min-Chul Kwon, Kim Monkhorst, et al.
Cell Reports|June 21, 2016
BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived XenograftsKristel Kemper, Oscar Krijgsman, Xiangjun Kong, et al.
Pageof 3